Home › research
 

Keywords :   


Tag: research

Landstar System Upgraded at Wolfe Research

2015-05-30 00:23:13| Trucking - Topix.net

Landstar System traded up 1.76% on Friday, hitting $65.40. The stock had a trading volume of 1,438,761 shares.

Tags: system research upgraded wolfe

 

Research in Focus - Coffee Craze Could Yet Drive Liqueurs

2015-05-29 13:54:00| Daily beverage news and comment - from just-drinks.com

The diverse liqueurs category has been becalmed in recent years, but the very diversity of the sector means that, while some areas might be declining, other areas are almost certain to be showing some growth.

Tags: research yet drive focus

 
 

Liqueurs set for slow global recovery - research

2015-05-29 12:57:00| Daily beverage news and comment - from just-drinks.com

The liqueurs category is set for "slow, steady growth" in the coming years, according to new research from just-drinks and The IWSR.

Tags: set research global slow

 

BASF Opens New Agricultural Research Station in Pune, India

2015-05-29 07:00:00| Coatings World Breaking News

Tags: research india station opens

 

Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA (pembrolizumab)

2015-05-28 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & SEATTLE Collaboration Builds on Mercks R&D and NanoStrings Biomarker Development Leadership Positions in Immuno-Oncology Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in multiple tumor types. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orNanoString Investor/Media Relations:Leigh Salvo, 415-513-1281 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NSTG Exchange: NASDAQ read more

Tags: for research development program

 

Sites : [682] [683] [684] [685] [686] [687] [688] [689] [690] [691] [692] [693] [694] [695] [696] [697] [698] [699] [700] [701] next »